The company has pioneered the isolation, engineering, and clinical development of products that target angiogenesis in-vivo, demonstrating the efficiency of human monoclonal antibodies in targeting tumor neo-vasculature in animal models and cancer patients. Philogen has four anti-cancer antibody derivatives and an antibody derivative for the treatment of rheumatoid arthritis in clinical studies, with two registrational studies in planning. The R&D unit, Philochem, is based in Zurich and isolates the most promising candidate products, while pharmaceuticals are produced in Siena according to GMP standards and advanced to clinical trials. Philogen generates revenue from a diversified range of activities, has signed agreements with major pharmaceutical companies, and owns a diversified portfolio of international patents, with a majority of revenue derived from the USA.